Autoantibody biomarkers for the detection of serous ovarian cancer

Highlights • Screened a total of 10,247 human antigens using customizable protein microarrays • Performed orthogonal ELISA assay to validate 39 candidate autoantibody biomarkers • Defined a panel of biomarkers with 45% sensitivity at > 99% specificity to screen for serous ovarian cancer

Saved in:
Bibliographic Details
Published inGynecologic oncology Vol. 146; no. 1; pp. 129 - 136
Main Authors Katchman, Benjamin A, Chowell, Diego, Wallstrom, Garrick, Vitonis, Allison F, LaBaer, Joshua, Cramer, Daniel W, Anderson, Karen S
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.07.2017
Subjects
Antibodies, Neoplasm - blood
Antibodies, Neoplasm - immunology
Antigens, Neoplasm - blood
Antigens, Neoplasm - immunology
Autoantibodies - blood
Autoantibodies - immunology
Autoantibody
Biomarker
Biomarkers, Tumor - blood
Biomarkers, Tumor - immunology
Case-Control Studies
Cystadenocarcinoma, Serous - blood
Cystadenocarcinoma, Serous - immunology
Diagnostics
Female
Hematology, Oncology and Palliative Medicine
Humans
Middle Aged
Obstetrics and Gynecology
Ovarian cancer
Ovarian Neoplasms - blood
Ovarian Neoplasms - immunology
Protein Array Analysis
Proteomics
Ab
In vitro transcription and translation
Biomarker
nucleic acid programmable protein arrays
Diagnostics
Antibody
SOC
NAPPA
Autoantibody
TAAb
IVTT
Ovarian cancer
Proteomics
tumor antigen-associated autoantibody
serous ovarian cancer
Online AccessGet full text

Cover

More Information
Summary:Highlights • Screened a total of 10,247 human antigens using customizable protein microarrays • Performed orthogonal ELISA assay to validate 39 candidate autoantibody biomarkers • Defined a panel of biomarkers with 45% sensitivity at > 99% specificity to screen for serous ovarian cancer
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0090-8258
1095-6859
DOI:10.1016/j.ygyno.2017.04.005